TheraSphere Y-90 (Liver Cancer Treatment System)

2021: Announcement TheraSphere Y-90 - Liver Cancer Treatment Systems

In mid-March 2021, Boston Scientific introduced a new device for the treatment of liver cancer. According to the press release, glass microspheres of TheraSphere Y-90 were developed for treatment of patients with a hepatocellular carcinoma (GCK).

Regulators have allowed Y-90 TheraSphere to be put on the market, which has allowed patients access to the latest therapy, which has so far been used exclusively in clinical research to help hopelessly ill patients. Boston Scientific said it is currently the only radioembolization technology recommended for the treatment of inoperable HCC in the United States. At the same time, a patient receiving TheraSphere therapy does not need hospitalization, since treatment can be carried out in an outpatient setting, and the procedure takes only one hour.

Liver Cancer Treatment System TheraSphere Y-90

The Y-90 TheraSphere device provides selective internal radiation therapy (SIRT) with low toxicity. The therapy system consists of millions of microscopic glass beads containing radioactive yttrium (Y-90). Glass beads are delivered directly to the tumor through a catheter to limit the effects of radiation therapy on surrounding healthy tissues as much as possible.

In a Legacy study involving 162 participants to assess the safety and efficacy of therapy in HCC, favorable results were achieved. After two courses of TheraSphere therapy, 100% of patients had a complete or partial response, and the total three-year survival in patients with graft or resection after treatment was 93%.

Over 20 years of clinical research, TheraSphere has demonstrated improvements in survival and quality of life in more than 70,000 patients worldwide, said Peter Pattison, president of Boston Scientific's intervention oncotherapy unit. - We also plan to conduct a randomized trial to examine the combination of TheraSphere and immunotherapy in HCC patients. [1]]

Notes